Minocycline in lepromatous leprosy.
Twelve patients were treated with three dose levels of minocycline for 30 days, primarily to detect the dose-related effects on Mycobacterium leprae viability, followed by another 5 months of daily minocycline for overall efficacy and persistence of clinical and antibacterial effects. Subsequently, the patients were given standard WHO/MDT chemotherapy for multibacillary leprosy. Clinical improvement was recognizable during the first month, occurring much earlier among those on minocycline 200 mg daily than those who received minocycline 100 mg daily. A similar change also was observed in one patient 11 days after three daily doses of 100 mg of minocycline. At the end of 6 months, all patients were clinically improved with a slight reduction in the average bacterial index (BI) and logarithmic index of bacilli in biopsy (LIB). The effects of minocycline on viability by mouse foot pad inoculation and palmitic acid oxidation assays were noted beginning at 10 to 14 days of daily dosing and becoming more definite after 30 days of treatment. Both tests correlated fairly well. Doses of 200 mg daily did not appear to be more efficient than minocycline 100 daily. Phenolic glycolipid-I (PGL-I) antigen determinations done on some patients during the first month remained positive and did not correlate with changes in viability results. At the end of 6 months, after 5 months of 100 mg of minocycline monotherapy, no viable organisms could be demonstrated by mouse foot pad inoculation and palmitic acid oxidation assays; assays for PGL-I antigen were all negative.(ABSTRACT TRUNCATED AT 250 WORDS)
Fajardo
T T
TT
Clinical Research Branch, Leonard Wood Memorial Center, Cebu City, The Philippines.
Villahermosa
L G
LG
dela Cruz
E C
EC
Abalos
R M
RM
Franzblau
S G
SG
Walsh
G P
GP
D000328:Adult; D000818:Animals; D000942:Antigens, Bacterial; D015169:Colony Count, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006017:Glycolipids / Q000032:analysis; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use; D015439:Leprosy, Borderline / Q000188:drug therapy* / Q000382:microbiology; D015440:Leprosy, Lepromatous / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D008911:Minocycline / Q000008:administration & dosage / Q000627:therapeutic use*; D009166:Mycobacterium leprae / Q000254:growth & development; D014944:World Health Organization
D000942:Antigens, Bacterial; D006017:Glycolipids; D007917:Leprostatic Agents; C045169:phenolic glycolipid I, Mycobacterium leprae; D008911:Minocycline